INT182427

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2005
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 2.78
Pain Relevance 1.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (E2F2) nucleus (E2F2) DNA binding (E2F2)
transcription factor binding (E2F2)
Anatomy Link Frequency
H69 1
E2F2 (Homo sapiens)
Pain Link Frequency Relevance Heat
qutenza 260 99.70 Very High Very High Very High
Inflammation 22 96.48 Very High Very High Very High
cytokine 5 95.44 Very High Very High Very High
withdrawal 5 91.44 High High
COX2 10 86.28 High High
agonist 30 55.08 Quite High
antagonist 5 38.24 Quite Low
imagery 1 20.48 Low Low
cINOD 10 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Small Cell Lung Cancer 126 99.54 Very High Very High Very High
Retinoblastoma 5 98.16 Very High Very High Very High
Cancer 143 97.12 Very High Very High Very High
INFLAMMATION 27 96.48 Very High Very High Very High
Pancreatic Cancer 5 94.56 High High
Contagious Ecthyma 1 93.04 High High
Obesity 10 80.40 Quite High
Lung Cancer 25 70.48 Quite High
Leukemia 12 69.12 Quite High
Apoptosis 127 68.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Finally, chromatin IP (ChIP) analysis of human SCLC cells demonstrated that treatment of capsaicin decreased the recruitment of activator E2Fs, namely E2F2 and E2F3, to proliferative promoters like cyclin E, TS, cdc25A and cdc6.
E2F2 Binding (recruitment) of associated with qutenza and small cell lung cancer
1) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.65 Pain Relevance 0.93
Control H69 SCLC cells contained E2F1, E2F2 and E2F3 bound to proliferative promoters.
E2F2 Binding (bound) of in H69 associated with small cell lung cancer
2) Confidence 0.22 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2857654 Disease Relevance 0.57 Pain Relevance 0.31
inhibition of E2F/DP DNA binding [129], the inhibition of cyclins D1 and E,
E2F Binding (binding) of
3) Confidence 0.04 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.35 Pain Relevance 0.14
the phosphorylation of pRb, but also decreases the amount of “free” E2F
E2F Binding (amount) of
4) Confidence 0.03 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.09 Pain Relevance 0
When

hyperphosphorylated, pRB cannot bind to E2F transcription factors that can

E2F Neg (cannot) Binding (bind) of
5) Confidence 0.03 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.10 Pain Relevance 0
increasing the amount of hypophosphorylated pRb able to bind E2F.
E2F Binding (bind) of
6) Confidence 0.03 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.53 Pain Relevance 0.04
when hypophosphorylated, binds and inactivates the E2F transcription factor

[105].

E2F Binding (binds) of
7) Confidence 0.03 Published 2008 Journal PPAR Research Section Body Doc Link PMC2443425 Disease Relevance 0.41 Pain Relevance 0.07
However, the mouse OGG1 gene also contains putative binding sites for NF-Y (position 2028–2040) and E2F (positions 967–974 and 231–240).
E2F Binding (binding) of
8) Confidence 0.02 Published 2005 Journal Nucleic Acids Research Section Body Doc Link PMC1072800 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox